Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
173 hedge funds and large institutions have $1.85B invested in Akero Therapeutics in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 74 increasing their positions, 45 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
64% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 45
32% more capital invested
Capital invested by funds: $1.4B → $1.85B (+$443M)
10% more funds holding
Funds holding: 157 → 173 (+16)
1.84% less ownership
Funds ownership: 107.88% → 106.04% (-1.8%)
24% less call options, than puts
Call options by funds: $15.3M | Put options by funds: $20M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$82.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$56M |
| 3 |
RI
RTW Investments
New York
|
+$44.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$43.6M |
| 5 |
FAM
Fred Alger Management
New York
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$41.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$31.8M |
| 3 |
CC
Commodore Capital
New York
|
-$13.2M |
| 4 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$11.8M |
| 5 |
Alkeon Capital Management
New York
|
-$10.5M |
AKRO Hedge Fund Activity: Q1 2024 in Review
173 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2024, worth a combined $1.85B — up 32% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AKRO positions and 21 closed out — a net gain of 16 holders — while 74 added to existing stakes and 45 trimmed.
The largest buyer was General Atlantic, adding an estimated $82.8M. The largest seller was Morgan Stanley, cutting an estimated $41.1M.
- 173 institutional investors held Akero Therapeutics (AKRO) as of Q1 2024, up from 157 in Q4 2023.
- Funds reported $1.85B of Akero Therapeutics stock for Q1 2024, up 32% quarter-over-quarter.
- 37 funds opened new Akero Therapeutics positions in Q1 2024 and 21 closed out, a net change of +16 holders.
- The largest Akero Therapeutics buyer in Q1 2024 was General Atlantic, an estimated $82.8M added.
- The largest Akero Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $41.1M sold.
Based on aggregated 13F filings for Q1 2024.